|
Post by lennymnkd on Jan 5, 2017 8:40:02 GMT -5
Can or will any clarity be said at the JP Morgan conference/ on the 11th ?
|
|
|
Post by silentknight on Jan 5, 2017 8:46:01 GMT -5
So Amgen is buying Mannkind now? I don't think so for a second but there are those that do. If Amgen wanted MNKD, they could have bought them out at any point after the SNY debacle was over. Having two former officers from Amgen on MNKD's payroll is not indicative of a buyout, in my opinion but people like to speculate. If Amgen wants MNKD, then we're all going to be rich. According to others, they're going to be in a bidding war with Sanofi. Lol.
|
|
|
Post by dictatorsaurus on Jan 5, 2017 8:49:02 GMT -5
So Amgen is buying Mannkind now? I don't think so for a second but there are those that do. If Amgen wanted MNKD, they could have bought them out at any point after the SNY debacle was over. Having two former officers from Amgen on MNKD's payroll is not indicative of a buyout, in my opinion but people like to speculate. If Amgen wants MNKD, then we're all going to be rich. According to others, they're going to be in a bidding war with Sanofi. Lol. And google, and Bill Gates. Heck might as well get Trump tweeting about his offer. His tower in NY can be the new headquarter. Joking aside, Mannkind doesn't seem to be able to get a partner, let alone a complete take over. Sad.
|
|
|
Post by brentie on Jan 5, 2017 9:04:30 GMT -5
|
|
|
Post by doingmybest on Jan 5, 2017 9:13:46 GMT -5
This is great news. A proven track record and loads of experience can only help this product get out to the field. In my opinion however, the approach has been flawed since inception. The product needs to be marketed to the END USER...not the physicians. The end user who injects several times daily needs to be made aware of this excellent convenient alternative to their diabetes related medical needs. Who would prefer injections over an inhaler? Physicians generally are very busy and the last thing they are motivated to do is to suggest an alternative solution for the patient which may require pulmonary testing, dose determinations and closer monitoring of the patient during the transition period. Of course, this recommendation on their part also includes a bit of risk. This is not to say physicians do not have their patients best interest in mind, but more so, they take the path of least resistance and effort...steady as she goes with the current treatment...unless the PATIENT inquires about Afrezza. Once the PATIENT hears about a diabetes treatment as simple as using an inhaler, then the physician will respond, and the trials will begin, and the prescriptions will start flying off the shelves. Lets see some prime time television advertising and satellite radio ads promoting this excellent product. Market to the END USER...they are the ones who really matter.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 5, 2017 9:39:02 GMT -5
So Amgen is buying Mannkind now? Sure, why not?! It's the new year and time to recycle the old hopes. Maybe we'll revisit google, sny, my personal favorite - bill gates, and any company that has an office within a 100 miles radius of anything mnkd. MNKD will transform this year one way or another. IF the stock price doesn't get up above a buck a share in a few months, a letter will be sent to mnkd likely indicating a delisting date from the exchange. This, as many have pointed out, doens't mean anything to mnkd as a company - they are still mannkind, they still own afrezza. But it means everything when it comes to accessing investor cash. Without the exchange, mnkd has to raise funds privately. With their balance sheet and lack of sales, mnkd is literally holding their hat in their hands and are essentially street beggers. Is apple a street begger? Nope, they fart cash. MNKD bleeds cash. And that brings the point to a potential buyer. Exactly how would those conversations go between mnkd and potential buyers? how much do you negotiate with street beggers when you open up your wallet to give? Or how much do you pay for something at a garage sale? Full price? I have a habit of opening my wallet from time to time and simply giving whatever it is I have in cash to whomever is begging on the corner. Not exactly a negotiation and it wouldn't be for mnkd either. What's as likely as any scenario at this point is mnkd is taken private. No point in trying to buy mnkd as it currently stands (too much financial baggage) so picking up the pieces in bankruptcy is the likely outcome while getting rid of debt holders for pennies on the dollar. This would be the best outcome for afrezza users as the drug has a chance of continuing and the worst outcome for existing shareholders as they would be wiped out. However, I tend to be ultra conservative and suspect that if nobody was interested in buying afrezza two years ago (or 3 or 4 or 5 or 6...) when the hype was more real than ever, who wants to lay out big cash now after two years of sales failure? The biggest fear for users is that nobody picks up the pieces and afrezza simply sits in the aether.
|
|
|
Post by lakon on Jan 5, 2017 10:54:26 GMT -5
So Amgen is buying Mannkind now? Sure, why not?! It's the new year and time to recycle the old hopes. Maybe we'll revisit google, sny, my personal favorite - bill gates, and any company that has an office within a 100 miles radius of anything mnkd. MNKD will transform this year one way or another. IF the stock price doesn't get up above a buck a share in a few months, a letter will be sent to mnkd likely indicating a delisting date from the exchange. This, as many have pointed out, doens't mean anything to mnkd as a company - they are still mannkind, they still own afrezza. But it means everything when it comes to accessing investor cash. Without the exchange, mnkd has to raise funds privately. With their balance sheet and lack of sales, mnkd is literally holding their hat in their hands and are essentially street beggers. Is apple a street begger? Nope, they fart cash. MNKD bleeds cash. And that brings the point to a potential buyer. Exactly how would those conversations go between mnkd and potential buyers? how much do you negotiate with street beggers when you open up your wallet to give? Or how much do you pay for something at a garage sale? Full price? I have a habit of opening my wallet from time to time and simply giving whatever it is I have in cash to whomever is begging on the corner. Not exactly a negotiation and it wouldn't be for mnkd either. What's as likely as any scenario at this point is mnkd is taken private. No point in trying to buy mnkd as it currently stands (too much financial baggage) so picking up the pieces in bankruptcy is the likely outcome while getting rid of debt holders for pennies on the dollar. This would be the best outcome for afrezza users as the drug has a chance of continuing and the worst outcome for existing shareholders as they would be wiped out. However, I tend to be ultra conservative and suspect that if nobody was interested in buying afrezza two years ago (or 3 or 4 or 5 or 6...) when the hype was more real than ever, who wants to lay out big cash now after two years of sales failure? The biggest fear for users is that nobody picks up the pieces and afrezza simply sits in the aether. Point taken. Since you mentioned Apple, take a look at a little history. Time is always against us. Who is most likely willing to buy a little more time? Those who are otherwise likely to lose the most. Between Apple and Microsoft, there was the matter of litigation, but it's still instructive to see what $150 million dollars helped accomplish. Few ever see the potential until long after the event, as demonstrated by Microsoft's BUY and SELL of Apple's stock. www.wired.com/2009/08/dayintech_0806/www.engadget.com/2014/05/20/what-ever-became-of-microsofts-150-million-investment-in-apple/www.ibtimes.co.uk/microsofts-biggest-mistake-investing-apple-was-craziest-thing-we-ever-did-1525752www.forbes.com/sites/ericjackson/2012/03/01/steve-jobs-used-patents-to-get-bill-gates-to-make-1997-investment-in-apple/#3acd9ba95d6a"In a way, you could say it might have been the craziest thing we ever did. But, you know, they've taken the foundation of great innovation, some cash, and they've turned it into the most valuable company in the world." (Steve Ballmer) MNKD has the potential to bring forth a golden age of endocrinology. Oddly enough, the quote feels just as pertinent now for MNKD as it did then for AAPL. $1 million - RLS (2016) $20 million - Valencia $30 million - The Mann Group MNKD has to come up with about another $100 million to make it to about July 4th, 2018. That would be 2 years of trying commercialization by themselves. Last I checked, Mann affiliated entities owned 10's of millions in real estate as does the current Chairman of the Board... How much cash can the Mann Group access? Who are the major debt holders? How big will the RLS milestone payments be for 2017 and 2018? How much will the Epi, Trep, and Pal be worth? When will sales ramp? Will TV spots help? Things are not going well at the moment, but perhaps, they are not as dire as some make them out to be.
|
|
|
Post by peppy on Jan 5, 2017 11:18:26 GMT -5
I hope Dr. Tross consulted with Proboards Matt before making this decision to leave his executive job at Amgen. Apparently if MNKD doesn't announce a R/S within the next two weeks they will go bankrupt. Dr.Tross may not know this. Good point.
|
|
|
Post by lakon on Jan 5, 2017 13:13:06 GMT -5
I hope Dr. Tross consulted with Proboards Matt before making this decision to leave his executive job at Amgen. Apparently if MNKD doesn't announce a R/S within the next two weeks they will go bankrupt. Dr.Tross may not know this. Good point. I'm not too worried about bankruptcy, R/S, or delisting anytime soon. It's not like the NASDAQ enforces Reg SHO so why are the ProBoards "experts" such believers in NASDAQ enforcing the rules? They are a SRO, right? Game it! Everybody else does. (I am worried about refills and being top heavy without progress.) Time will tell. business.nasdaq.com/media/Nasdaq%20Initial%20Listing%20Guide_tcm5044-13919.pdflistingcenter.nasdaq.com/assets/continuedguide.pdfnasdaq.cchwallstreet.com/NASDAQTools/PlatformViewer.asp?selectednode=chp%5F1%5F1%5F4%5F3%5F6%5F5&manual=%2Fnasdaq%2Fmain%2Fnasdaq%2Dequityrules%2Flistingcenter.nasdaq.com/NonCompliantCompanyList.aspxMNKD Bid Price NGM 9/14/2016TST Bid Price NGM 12/14/2016 (Shall we take bets on whether MNKD or TST lasts longer?) "(A) Bid PriceA failure to meet the continued listing requirement for minimum bid price shall be determined to exist only if the deficiency continues for a period of 30 consecutive business days. Upon such failure, the Company shall be notified promptly and shall have a period of 180 calendar days from such notification to achieve compliance. Compliance can be achieved during any compliance period by meeting the applicable standard for a minimum of 10 consecutive business days during the applicable compliance period, unless Staff exercises its discretion to extend this 10 day period as discussed in Rule 5810(c)(3)(F). (i) Global Select Market and Global MarketIf a Company listed on The Nasdaq Global Market has not been deemed in compliance prior to the expiration of the 180 day compliance period, it may transfer to The Nasdaq Capital Market, provided that it meets the applicable market value of publicly held shares requirement for continued listing and all other applicable requirements for initial listing on the Capital Market (except for the bid price requirement) based on the Company's most recent public filings and market information and notifies Nasdaq of its intent to cure this deficiency. Following a transfer to The Nasdaq Capital Market, the Company will be afforded the remainder of the applicable compliance period set forth in Rule 5810(c)(3)(A)(ii), unless it does not appear to Nasdaq that it is possible for the Company to cure the deficiency. The Company may also request a hearing to remain on The Nasdaq Global Market pursuant to the Rule 5800 Series. Any time spent in the hearing process will not extend the length of the remaining applicable compliance periods on The Nasdaq Capital Market afforded by this rule. (ii) Capital MarketIf a Company listed on the Capital Market is not deemed in compliance before the expiration of the 180 day compliance period, it will be afforded an additional 180 day compliance period, provided that on the 180th day of the first compliance period it meets the applicable market value of publicly held shares requirement for continued listing and all other applicable standards for initial listing on the Capital Market (except the bid price requirement) based on the Company's most recent public filings and market information and notifies Nasdaq of its intent to cure this deficiency. If a Company does not indicate its intent to cure the deficiency, or if it does not appear to Nasdaq that it is possible for the Company to cure the deficiency, the Company will not be eligible for the second grace period. If the Company has publicly announced information (e.g., in an earnings release) indicating that it no longer satisfies the applicable listing criteria, it shall not be eligible for the additional compliance period under this rule. "
|
|
|
Post by dreamboatcruise on Jan 5, 2017 14:45:58 GMT -5
I don't think so for a second but there are those that do. If Amgen wanted MNKD, they could have bought them out at any point after the SNY debacle was over. Having two former officers from Amgen on MNKD's payroll is not indicative of a buyout, in my opinion but people like to speculate. If Amgen wants MNKD, then we're all going to be rich. According to others, they're going to be in a bidding war with Sanofi. Lol. And google, and Bill Gates. Heck might as well get Trump tweeting about his offer. His tower in NY can be the new headquarter. Joking aside, Mannkind doesn't seem to be able to get a partner, let alone a complete take over. Sad. Well to take a page from Trump. Some people are saying the Saudi royal family is interested in buying MNKD. [caveat... that someone was me... and I made it up]
|
|
|
Post by tw12 on Jan 5, 2017 15:37:30 GMT -5
This is great news. A proven track record and loads of experience can only help this product get out to the field. In my opinion however, the approach has been flawed since inception. The product needs to be marketed to the END USER...not the physicians. The end user who injects several times daily needs to be made aware of this excellent convenient alternative to their diabetes related medical needs. Who would prefer injections over an inhaler? Physicians generally are very busy and the last thing they are motivated to do is to suggest an alternative solution for the patient which may require pulmonary testing, dose determinations and closer monitoring of the patient during the transition period. Of course, this recommendation on their part also includes a bit of risk. This is not to say physicians do not have their patients best interest in mind, but more so, they take the path of least resistance and effort...steady as she goes with the current treatment...unless the PATIENT inquires about Afrezza. Once the PATIENT hears about a diabetes treatment as simple as using an inhaler, then the physician will respond, and the trials will begin, and the prescriptions will start flying off the shelves. Lets see some prime time television advertising and satellite radio ads promoting this excellent product. Market to the END USER...they are the ones who really matter.
As we know, MannKind's strategy is first to create endo and PCP fluency with Afrezza. Then when patient demand is generated by advertising, it is met with a knowledgable response by doctors, thus making much more likely a successful adoption of the product -- also largely avoiding the negative result of creating a curiosity about Afrezza that is simply not reciprocated by an uninformed medical community. But for my money (literally!), it now seems well past time when a national advertising campaign should be launched, to expand dramatically the conversation among diabetics, their families, and doctors about Afrezza's unique efficacy, a conversation that should rapidly translate into wide and successful demand for product. And here's a suggested headline for new copy: "AFREZZA, THE INSPIRED INSULIN!"
|
|
|
Post by lennymnkd on Jan 5, 2017 15:56:19 GMT -5
Tw/ a good portion of your message is what Matt and ray have been telling us right along ... a much longer approach but a much needed one a very innovated "product" ... with a learning curve ...
|
|
|
Post by peppy on Jan 5, 2017 16:07:49 GMT -5
This is great news. A proven track record and loads of experience can only help this product get out to the field. In my opinion however, the approach has been flawed since inception. The product needs to be marketed to the END USER...not the physicians. The end user who injects several times daily needs to be made aware of this excellent convenient alternative to their diabetes related medical needs. Who would prefer injections over an inhaler? Physicians generally are very busy and the last thing they are motivated to do is to suggest an alternative solution for the patient which may require pulmonary testing, dose determinations and closer monitoring of the patient during the transition period. Of course, this recommendation on their part also includes a bit of risk. This is not to say physicians do not have their patients best interest in mind, but more so, they take the path of least resistance and effort...steady as she goes with the current treatment...unless the PATIENT inquires about Afrezza. Once the PATIENT hears about a diabetes treatment as simple as using an inhaler, then the physician will respond, and the trials will begin, and the prescriptions will start flying off the shelves. Lets see some prime time television advertising and satellite radio ads promoting this excellent product. Market to the END USER...they are the ones who really matter.
As we know, MannKind's strategy is first to create endo and PCP fluency with Afrezza. Then when patient demand is generated by advertising, it is met with a knowledgable response by doctors, thus making much more likely a successful adoption of the product -- also largely avoiding the negative result of creating a curiosity about Afrezza that is simply not reciprocated by an uninformed medical community. But for my money (literally!), it now seems well past time when a national advertising campaign should be launched, to expand dramatically the conversation among diabetics, their families, and doctors about Afrezza's unique efficacy, a conversation that should rapidly translate into wide and successful demand for product. And here's a suggested headline for new copy: "AFREZZA, THE INSPIRED INSULIN!" Afrezza, technosphere insulin, first phase and second phase insulin response.
I like to treat people like they have a brain. www.screencast.com/t/pYQ4TMFaY afrezzadownunder.com/
|
|
|
Post by kc on Jan 5, 2017 16:24:26 GMT -5
You have to have Patience to get the Dr's and Endo's onboard to get the Patients. We all including management thought it was as easy a flipping a switch on. But we now know that Dr's don't change what is working or not working for Patients. They are very conservative and perhaps have tunnel vision so they don't make any moves very fast.
We are stuck in a cycle that might take several years if we have the finances to hold on. Afrezza usage has been totally patient drive and viral.
Can MannKind survive until people get Afrezza without begging a Dr for it?
Some of that will be driver if the price of Afrezza can be lower than the competition. But just stating that we have not increased prices like the other insulin products is not a good sales strategy.
Maybe Afrezza needs to get down in the gutter and be priced comparable to Generic Insulin's. Hate to create a price war but if the product does not survive because it can't get tier status on tier pricing, then how else do you get it in the hands of consumers?
One final point and I have said this many times in the last year. The board of Directors should put MannKind up for sale before they every would consider bankruptcy. In a bankruptcy situation only the secured creditors get a chance of some equity. The common shareholder is wiped out. So why not sell the company for $5.00 or $10.00 whatever they can get vs. filing chapter 11. Personally I think there will be a resolution like as just the product
Afrezza is too good not to make it worldwide. But today we suffer from lack of capital and that can't be resolved without a game changing event like a buyout.
|
|
|
Post by dictatorsaurus on Jan 5, 2017 16:40:23 GMT -5
The current pricing is a MAJOR hurdle and it's preventing partnerships from materializing. Especially international markets, which tend to price drugs lower than the US.
|
|